Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia

Cyrsvita® is available in 10mg/mL, 20mg/mL, or 30mg/mL dosage strengths in a single-dose vial for subcutaneous administration. Image courtesy of Marco Verch.



  • Cyrsvita®
  • Cyrsvita®
  • Cyrsvita®

Go Top